Navigation Links
Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting

llaboration with Novartis covering Genelabs' non-nucleoside HCV polymerase inhibitors.

"The data presented today clearly support the further investigation of non-nucleoside polymerase inhibitors for the future treatment of HCV infection," said Ronald C. Griffith, Ph.D., Genelabs' Chief Scientific Officer. "Furthermore, we believe future treatment of HCV is likely to involve combinations of antiviral drugs and these data suggest that combinations of this type of non-nucleoside agent with interferon or other likely therapeutic drugs, such as nucleoside chain terminators or protease inhibitors, may be feasible."

About Genelabs Technologies

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit www.genelabs.com.

NOTE: Genelabs(R) and the Genelabs logo are registered trademarks and Prestara(TM) is a trademark of Genelabs Technologies, Inc.

NOTE ON FORWARD LOOKING STATEMENTS AND RISKS: This press release contains forward-looking statements including statements on the feasibility of non-nucleoside polymerase inhibitors for the future treatment of HCV infection and the prospects fo
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:9/29/2014)... , Sept. 29, 2014 Pharmaceutical Care Management ... today outlined policy solutions that could reduce prescription fraud ... Hill briefing, " Prescription Opioid Abuse: Fighting Back on ... Reform and PCMA. The briefing featured ... prescription drug abuse and fraud. The Centers for Disease ...
(Date:9/29/2014)... , Sept. 29, 2014 EU5 Sigmoidoscopes ... new report, "EU5 Sigmoidoscopes Market Outlook to 2020", ... market. The report provides value, in millions of ... (in US dollars) within market segments - Flexible ... and Flexible Non-Video (Fibre) Sigmoidoscopes). The ...
(Date:9/29/2014)... SAN DIEGO , 29 de septiembre de 2014 ... adelante, Daiichi Sankyo) (TSE: 4568) y Ambit Biosciences (NASDAQ: ... que han llegado a un acuerdo de fusión definitivo ... acciones ordinarias de Ambit Biosciences a un precio de ... una oferta de licitación seguida de una fusión con ...
Breaking Medicine Technology:PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2EU5 Sigmoidoscopes Market Outlook to 2020 2EU5 Sigmoidoscopes Market Outlook to 2020 3Daiichi Sankyo adquiere Ambit Biosciences 2Daiichi Sankyo adquiere Ambit Biosciences 3Daiichi Sankyo adquiere Ambit Biosciences 4Daiichi Sankyo adquiere Ambit Biosciences 5Daiichi Sankyo adquiere Ambit Biosciences 6Daiichi Sankyo adquiere Ambit Biosciences 7Daiichi Sankyo adquiere Ambit Biosciences 8
... safety profile of BSI-201 in ... subjects with advanced solid tumors -, BRISBANE, Calif., ... developing novel cancer therapies,today announced that data supporting its lead ... of Clinical Oncology annual,meeting in Chicago., Findings will be ...
... SGP ), a leader in advancing the ... infection, announced today that data from,several clinical studies ... therapy, as well as boceprevir, the,company,s investigational oral ... annual Digestive Disease Week (DDW) meeting to be ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 ... now offering gum depigmentation treatments for dark gums. Dark ... can make people feel extremely self-conscious about their smiles. ... or dark gums. “I am one of the few ... and I have treated celebrities, business leaders, high-ranking officials ...
(Date:9/30/2014)... In books and movies, plots involving older men chasing ... suggests that the stereotype may be grounded in fact. ... than 12,000 people from Finland. The researchers, led by ... women typically preferred men who were the same age or ... On the other hand, men tended to have a lifelong ...
(Date:9/30/2014)... Sept. 30, 2014 (HealthDay News) -- For millions of ... excess weight and the threat of type 2 diabetes. ... may be tougher for some than for others, depending ... good health, it may not be as effective for ... 2 diabetes," said one expert, Dr. Ruth Loos, director ...
(Date:9/30/2014)... University of Michigan have described a new approach to ... the time needed for more traditional methods. , ... that is undergoing further investigation as a potential treatment ... , In research published online in the Proceedings ... the lab of Stephen Weiss at the U-M Life ...
(Date:9/30/2014)... Missouri (PRWEB) September 30, 2014 The ... that the SLUCare Physician Group, comprised of more than ... on a number of initiatives. With the recent ... network size, strengthening its market footprint to better respond ... Louis area. , SLPA is a physician-led clinically integrated ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:New discovery approach accelerates identification of potential cancer treatments 2Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2
... men has increased by 12% in six years, according to the ... diagnosed with the disease, 3,000 of those are men.// ... that they tend to occur more commonly on the back, whereas ... noticeable. Up to 77% of cases are caused by exposure to ...
... a mother's risk of having a hyperactive child. A ... the last three months of pregnancy had children with ... Glover, of Imperial College, London, told that this only ... frequently feeling scared.According to a survey antenatal anxiety ...
... somebody is likely to have an epileptic seizure. ,In ... warning and can lead to ,disability or even death. ... believe ,it may be possible to predict the onset ... ,An ECG records electrical activity from different parts of ...
... years. And while most of the popular remedies used in ... has increased. This powerful pill will //reduce pain, fever, inflammation, ... attacks and stroke. ,In the more than 35 ... few drugs have been developed that can even be compared ...
... one day have the option of having one blast ... up to 25 sessions afterwards, researchers said. //They believe ... for women and may improve the treatment of breast ... the developing world. ,Dr. Emiel Rutgers, of the ...
... new compounds developed for preventing and treating the flue ... only one dose to be effective.// The compounds, known ... flu drug relenza, or zanamivir, which the U.S. Food ... A and B. ,Researchers reported at the International ...
Cached Medicine News:
The 5539-7.5 linear transducer is a high frequency transducer dedicated to superficial and vascular imaging....
HST, versatile convex array abdominal transducer is multi-frequency, offering 5 levels of fundamental frequencies in addition to 4 settings of Harmonic frequencies. This transducer provides superb im...
Scan internal organs percutaneously while eliminating side lobe artifact....
... transducer is a curved ... the higher frequencies. Featuring ... this transducer provides exceptional ... frequency abdominal kidney bladder ...
Medicine Products: